2024/25年加拿大流感季延迟期间甲型H1N1pdm09和甲型H3N2流感疫苗效力的中期估计
Interim estimates of vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2) during a delayed influenza season, Canada, 2024/25.
作者信息
Separovic Lea, Zhan Yuping, Kaweski Samantha E, Sabaiduc Suzana, Carazo Sara, Olsha Romy, Mather Richard G, Dickinson James A, Hasso Maan, Meunier Isabelle, Jassem Agatha N, Zelyas Nathan, Gao Ruimin, Bastien Nathalie, Skowronski Danuta M
机构信息
British Columbia Centre for Disease Control, Vancouver, Canada.
Institut National de Santé Publique du Québec, Québec, Canada.
出版信息
Euro Surveill. 2025 Jan;30(4). doi: 10.2807/1560-7917.ES.2025.30.4.2500059.
The Canadian Sentinel Practitioner Surveillance Network (SPSN) reports interim 2024/25 vaccine effectiveness (VE) against acute respiratory illness due to laboratory-confirmed influenza during a delayed season of predominant A(H1N1)pdm09 and lower A(H3N2) co-circulation. Through mid-January, the risk of outpatient illness due to influenza A is reduced by about half among vaccinated vs unvaccinated individuals. Adjusted VE is 53% (95% CI: 36-65) against A(H1N1)pdm09, comprised of clades 5a.2a and 5a.2a.1, and 54% (95% CI: 29-70) against A(H3N2), virtually all clade 2a.3a.1.
加拿大哨兵执业者监测网络（SPSN）报告了2024/25年度在A（H1N1）pdm09占主导且A（H3N2）共同流行率较低的延迟季节中，针对实验室确诊流感所致急性呼吸道疾病的中期疫苗效力（VE）。截至1月中旬，接种疫苗者与未接种疫苗者相比，因甲型流感导致门诊疾病的风险降低了约一半。针对A（H1N1）pdm09（由5a.2a和5a.2a.1分支组成）的调整后疫苗效力为53%（95%CI：36-65），针对A（H3N2）（几乎全为2a.3a.1分支）的调整后疫苗效力为54%（95%CI：29-70）。
Zotero 插件